ORGO Organogenesis Holdings Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1661181 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-24.3%
TTM net income YoY-13,567.9%
TTM EPS YoY-1,400.0%
Revenue 3-yr CAGR-7.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-24.5%
Net margin-38.4%
FCF margin-0.0%
EBITDA margin-20.0%
Returns
ROE-72.2%
ROA-30.8%
ROIC (approx.)-47.0%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets28.8%
Debt / equity0.00x
Current ratio3.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.08x
Accruals ratio-33.2%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $564.17M | $482.04M |
| Cost of revenue | — | $115.74M |
| Gross profit | — | $366.30M |
| R&D expense | $44.54M | $50.27M |
| SG&A expense | $326.24M | $294.51M |
| Operating income | $44.69M | -$1.28M |
| Interest expense | -$2.28M | $1.54M |
| Pretax income | $46.97M | -$2.81M |
| Income tax | $9.94M | -$3.67M |
| Net income | $37.03M | $861,000 |
| EBITDA | $59.97M | $12.34M |
| EPS (basic) | 0.16 | -0.01 |
| EPS (diluted) | 0.15 | -0.01 |
| Weighted avg. shares (diluted) | 130.25M | 131.67M |
| Balance sheet | ||
| Cash & equivalents | $93.68M | $136.15M |
| Receivables | $217.45M | $109.86M |
| Inventory | $29.63M | $26.22M |
| Current assets | $362.19M | $285.94M |
| PP&E, net | $103.71M | $89.13M |
| Goodwill | $28.77M | $28.77M |
| Intangibles | $9.14M | $12.47M |
| Total assets | $598.73M | $497.89M |
| Current liabilities | $100.12M | $77.48M |
| Total liabilities | $164.81M | $112.57M |
| Shareholders' equity | $300.13M | $262.90M |
| Shares outstanding | 126.95M | 125.73M |
| Cash flow statement | ||
| Operating cash flow | -$10.31M | $14.21M |
| Capital expenditure | $14.15M | $10.03M |
| Free cash flow | -$24.46M | $4.18M |
| Investing cash flow | -$14.15M | -$10.03M |
| Financing cash flow | -$17.36M | $27.64M |
| Depreciation & amortization | $15.27M | $13.62M |
| Stock-based compensation | $13.30M | $10.58M |
| Share buybacks | — | $25.48M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.